The co-occurrence of cigarette smoking and unhealthy alcohol use
1 is common
2 and detrimental to health.
3 Among people with HIV infection, these behaviors are associated with increased risk of non-AIDS diseases.
4 Nicotine replacement therapy (NRT) and varenicline, a partial agonist of the α4β2 nicotinic acetylcholine receptor, are effective for smoking cessation, including among individuals with HIV.
5-7 Studies among smokers who drink alcohol demonstrate that varenicline reduces alcohol craving and consumption compared with placebo.
8,9 Cytisine, a plant-based partial agonist of the α4β2 nicotinic acetylcholine receptor, is effective for smoking cessation
10-12 and similar in efficacy to varenicline,
13,14 but its effects on alcohol consumption in humans are unknown.
15 Converging data support a role of nicotinic acetylcholine receptors in the consumption of alcohol, suggesting that they may serve as pharmacotherapeutic targets to treat risky drinking in addition to their established role in treating smoking.
16-19